Expired drugs possibly given to Nipah patients, says Keralam Health Minister
Source Entity
India Latest News: Top National Headlines Today & Breaking News | The Hindu
Kerala Health Minister K. Muraleedharan has ordered a probe into whether expired batches of Remdesivir, administered to Nipah patients between 2023 and 2025, contributed to fatalities. A medical board, led by Dr. Aravind R., will investigate the drug's distribution and any potential side effects.
Investigation Launched into Expired Remdesivir Use in Kerala
The Allegation and Official Response
The Kerala state government has initiated a formal investigation into the potential administration of expired Remdesivir to patients suffering from the Nipah virus. Health Minister K. Muraleedharan announced the formation of a specialized medical board during a session of the Keralam Legislative Assembly on October 29, 2026. This action follows a submission by Congress legislator Mathew Kuzhalnadan, who raised grave concerns regarding the integrity of the drug supply chain during past public health crises.
Scope of the Medical Inquiry
The inquiry will be led by Dr. Aravind R., the head of the Infectious Diseases department at the Government Medical College Hospital in Thiruvananthapuram. The board is tasked with a two-fold objective: first, to determine if the administration of expired batches of Remdesivir was a contributing factor in the deaths of Nipah patients between 2023 and 2025; and second, to identify if other patients who received the same medication experienced adverse side effects. This investigation is critical to reassessing the clinical outcomes of past outbreak management.
Historical Context and Political Implications
This probe arrives at a time when the state is revisiting its medical history. While the previous CPI(M)-led administration received significant international acclaim for its robust management of the COVID-19 and Nipah outbreaks, the current Congress-led government is now scrutinizing the administrative decisions made during those years. The transition from commendation to investigation highlights the volatility of public health governance and the necessity for rigorous accountability in medical supply chains.
The Role of Kerala Medical Services Corporation
Central to this investigation is the role of the Kerala Medical Services Corporation, which served as the exclusive distribution channel for Remdesivir to health institutions across the state. Remdesivir, an antiviral drug widely deployed during both the COVID-19 pandemic and subsequent Nipah virus outbreaks, was handled under emergency protocols. The probe will likely examine whether the urgency of these outbreaks led to lapses in inventory management or oversight that allowed expired stock to reach clinical settings.
Broader Implications for Public Health Safety
If the investigation confirms that expired medication was administered, it will necessitate a comprehensive overhaul of medical procurement and distribution protocols in Kerala. The findings may reveal gaps in the tracking of drug shelf-life during emergency response scenarios. This case serves as a stark reminder of the complexities inherent in managing large-scale medical stockpiles and the potential life-or-death consequences of supply chain failures.
Future Trends and Accountability
Looking ahead, the results of this medical board inquiry will likely set a precedent for how the state handles medical litigation and transparency regarding patient care. The public and medical community await the board's conclusions, which will be vital in restoring trust in the state's healthcare infrastructure. Ensuring that clinical standards are maintained, even during high-pressure emergency situations, remains the primary challenge for health authorities moving forward.
Verification Required?